Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657279 · ClinicalTrials.gov registry record · NA
Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial
A NA study, sponsored by Unity Health Toronto.
- Completed
- Registry status
- NA
- Development phase
- 111
- Enrollment target
NCT01657279: Completed NA study, sponsored by Unity Health Toronto.
NCT01657279 is a NA study that has completed, run by Unity Health Toronto. The registered enrollment target is 111 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01657279, a NA study, has completed, sponsored by Unity Health Toronto.
- COMPLETED
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
Study Summary
Background: Several risk score models are now available to assist clinicians estimate outcomes after an acute ischemic stroke. Limited information is available on the predictive value of these scores compared to real outcomes and clinical judgment. Objectives: To compare clinician judgment with the use of a validated stroke risk score (iScore) and patients' outcomes.
Interventions
- OTHER Clinical scenarios
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT01657279 record still lists
NCT01657279 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Clinical scenarios is the first listed.
NCT01657279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01657279 about?
NCT01657279 is a clinical study titled "Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial". Background: Several risk score models are now available to assist clinicians estimate outcomes after an acute ischemic stroke. Limited information is available on the predictive value of these scores compared to real outcomes and clinical judgment. Objectives: To compare clinician judgment with the...
What is the current status of trial NCT01657279?
This trial is currently completed. It is a NA study. The enrollment target is 111 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01657279?
The interventions under investigation include: Clinical scenarios (OTHER).
Who is sponsoring clinical trial NCT01657279?
This trial is sponsored by Unity Health Toronto, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01657279's enrollment target sits among peer trials
111 816th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia